-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Jefferies Financial Group Comments on Reneo Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:RPHM)
Jefferies Financial Group Comments on Reneo Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:RPHM)
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share (EPS) estimates for Reneo Pharmaceuticals in a research note issued on Friday, January 27th. Jefferies Financial Group analyst E. Yang expects that the company will post earnings of $3.86 per share for the year. The consensus estimate for Reneo Pharmaceuticals' current full-year earnings is ($2.16) per share.
Get Reneo Pharmaceuticals alerts:Reneo Pharmaceuticals Stock Down 1.1 %
Shares of Reneo Pharmaceuticals stock opened at $2.68 on Monday. The firm has a market cap of $65.74 million, a price-to-earnings ratio of -1.35 and a beta of 0.50. Reneo Pharmaceuticals has a 52-week low of $1.79 and a 52-week high of $6.46. The company's 50-day simple moving average is $2.32 and its 200-day simple moving average is $2.91.
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05.Institutional Investors Weigh In On Reneo Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Reneo Pharmaceuticals by 87.0% in the 3rd quarter. Renaissance Technologies LLC now owns 43,000 shares of the company's stock valued at $144,000 after buying an additional 20,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Reneo Pharmaceuticals in the third quarter valued at $62,000. Barclays PLC boosted its position in shares of Reneo Pharmaceuticals by 33.3% during the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock worth $241,000 after purchasing an additional 17,984 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Reneo Pharmaceuticals by 76.5% during the 2nd quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock worth $80,000 after purchasing an additional 13,000 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Reneo Pharmaceuticals in the 2nd quarter valued at about $457,000. Hedge funds and other institutional investors own 75.61% of the company's stock.
About Reneo Pharmaceuticals
(Get Rating)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share (EPS) estimates for Reneo Pharmaceuticals in a research note issued on Friday, January 27th. Jefferies Financial Group analyst E. Yang expects that the company will post earnings of $3.86 per share for the year. The consensus estimate for Reneo Pharmaceuticals' current full-year earnings is ($2.16) per share.
Reneo Pharmicals, Inc.(納斯達克股票代碼:RPHM — 獲取評級)——傑富瑞金融集團的研究分析師在1月27日星期五發布的一份研究報告中發佈了對Reneo Pharmicals的 FY2027 每股收益(EPS)估計。傑富瑞金融集團分析師E. Yang預計,該公司今年將公佈每股收益3.86美元。Reneo Pharmaceuticals目前全年收益的共識估計爲每股收益(2.16美元)。
Reneo Pharmaceuticals Stock Down 1.1 %
Reneo 製藥股價下跌1.1%
Shares of Reneo Pharmaceuticals stock opened at $2.68 on Monday. The firm has a market cap of $65.74 million, a price-to-earnings ratio of -1.35 and a beta of 0.50. Reneo Pharmaceuticals has a 52-week low of $1.79 and a 52-week high of $6.46. The company's 50-day simple moving average is $2.32 and its 200-day simple moving average is $2.91.
週一,Reneo Pharmicals股票開盤價爲2.68美元。該公司的市值爲6,574萬美元,市盈率爲-1.35,beta值爲0.50。Reneo Pharmicals的52周低點爲1.79美元,創52周高點6.46美元。該公司的50天簡單移動平均線爲2.32美元,其200天簡單移動平均線爲2.91美元。
Institutional Investors Weigh In On Reneo Pharmaceuticals
機構投資者對Reneo Pharmicals的看法
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Reneo Pharmaceuticals by 87.0% in the 3rd quarter. Renaissance Technologies LLC now owns 43,000 shares of the company's stock valued at $144,000 after buying an additional 20,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Reneo Pharmaceuticals in the third quarter valued at $62,000. Barclays PLC boosted its position in shares of Reneo Pharmaceuticals by 33.3% during the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock worth $241,000 after purchasing an additional 17,984 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Reneo Pharmaceuticals by 76.5% during the 2nd quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock worth $80,000 after purchasing an additional 13,000 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Reneo Pharmaceuticals in the 2nd quarter valued at about $457,000. Hedge funds and other institutional investors own 75.61% of the company's stock.
最近,許多機構投資者增加了或減少了在該業務中的股份。文藝復興科技有限責任公司在第三季度將其持有的Reneo Pharmicals的股票增加了87.0%。Renaissance Technologies LLC在此期間又購買了2萬股股票後,現在擁有該公司43,000股股票,價值14.4萬美元。Dimensional Fund Advisors LP在第三季度收購了價值62,000美元的Reneo Pharmicals的新巴克萊集團在第三季度將其在Reneo Pharmicals的股票頭寸提高了33.3%。巴克萊集團在上個季度又購買了17,984股股票後,現在擁有該公司71,930股股票,價值24.1萬美元。聯邦愛馬仕公司在第二季度將其在Reneo Pharmicals的股份增長了76.5%。Federated Hermes Inc.在此期間又購買了13,000股股票後,現在擁有該公司價值8萬美元的3萬股股票。最後,Citadel Advisors LLC在第二季度收購了Reneo Pharmicals股票的新頭寸,價值約爲45.7萬美元。對沖基金和其他機構投資者擁有該公司75.61%的股票。
About Reneo Pharmaceuticals
關於 Reneo 製藥
(Get Rating)
(獲取評分)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Reneo Pharmicals, Inc是一家處於臨床階段的製藥公司,專注於罕見遺傳線粒體疾病患者的療法的開發和商業化。其主要候選產品是 REN001,這是一種強效的選擇性過氧化物酶體增殖物激活受體 delta 的激動劑,正在臨床開發用於遺傳線粒體疾病,包括原發性線粒體肌病和長鏈脂肪酸氧化障礙。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
- 免費獲取 StockNews.com 關於 Reneo Pharmicals(RPHM)的研究報告的副本
- Yext A.I. 搜索平臺能否推動2023年的增長?
- Cassava Sciences 股票被低估了 124 美元的目標價?
- Constellation Brands:消費者在向下交易鐵路飲料嗎?
- Capital One 股票:次級貸款借款人會破壞漲勢嗎?
- MarketBeat Week 回顧 — 1/23-1/27
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收Reneo Pharmicals每日的新聞和收視率 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Reneo Pharmicals及相關公司最新新聞和分析師評級的簡明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧